Skip to main content

Advertisement

Log in

Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

The realisation that new chemical entities under development as drug candidates fail in three of four cases in clinical trials, together with increased costs and increased demands of reducing preclinical animal experiments, have promoted concepts for improvement of early screening procedures in humans. Positron emission tomography (PET) is a non-invasive imaging technology, which makes it possible to determine drug distribution and concentration in vivo in man with the drug labelled with a positron-emitting radionuclide that does not change the biochemical properties. Recently, developments in the field of rapid synthesis of organic compounds labelled with positron-emitting radionuclides have allowed a substantial number of new drug candidates to be labelled and potentially used as probes in PET studies. Together, these factors led to the logical conclusion that early PET studies, performed with very low drug doses—PET-microdosing—could be included in the drug development process as one means for selection or rejection of compounds based on performance in vivo in man. Another important option of PET, to evaluate drug interaction with a target, utilising a PET tracer specific for this target, necessitates a more rapid development of such PET methodology and validations in humans. Since only very low amounts of drugs are used in PET-microdosing studies, the safety requirements should be reduced relative to the safety requirements needed for therapeutic doses. In the following, a methodological scrutinising of the concept is presented. A complete pre-clinical package including limited toxicity assessment is proposed as a base for the regulatory framework of the PET-microdosing concept.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Scheme 1.
Fig. 1.
Fig. 2.
Fig. 3.

Similar content being viewed by others

References

  1. DiMasi JA (2001) Risks in new drug development: approval success rates for investigational drugs. Clin Pharm Ther 69:297–307

    Article  CAS  Google Scholar 

  2. Lesko LJ, Rowland M, Peck CC, Blaschke TF, Breimer D, de Jong HJ, Grahnen A, Kuhlmann JJ, Stewart B (2000) Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Eur J Pharm Sci 10:iv–xiv

    CAS  PubMed  Google Scholar 

  3. Reigner BG, Williams PE, Patel IH, Steimer JL, Peck C, van Brummelen P (1997) An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche. Clin Pharmacokinet 33:142–152

    CAS  PubMed  Google Scholar 

  4. Grahnen A, Karlsson MO (2001) Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials? Clin Pharmacokinet 40:317–325

    CAS  PubMed  Google Scholar 

  5. Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW Jr, Peck CC (2001) Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther 69:387–399

    Article  CAS  PubMed  Google Scholar 

  6. Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharm Ther 61:275–291

    CAS  Google Scholar 

  7. Barker J, Garner RC (1999) Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom. Rapid Commun Mass Spectrom13:285–293

    Article  Google Scholar 

  8. Garner RC, Barker J, Flavell C, Garner JV, Whattam M, Young GC, Cussans N, Jezequel S, Leong D (2000) A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. J Pharm Biomed Anal 24:197–209

    Article  CAS  PubMed  Google Scholar 

  9. Garner RC (2000) Accelerator mass spectrometry in pharmaceutical research and development—a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 1:205–213

    CAS  PubMed  Google Scholar 

  10. Langstrom B, Kihlberg T, Bergstrom M, Antoni G, Bjorkman M, Forngren BH, Forngren T, Hartvig P, Markides K, Yngve U, Ogren M (1999) Compounds labelled with short-lived β+-emitting radionuclides and some applications in life sciences. The importance of time as a parameter. Acta Chem Scand 53:651–669

    CAS  PubMed  Google Scholar 

  11. Kihlberg T, Karimi F, Långström B (2002 [11C] Carbon monoxide in selenium-mediated synthesis of 11C-carbamoyl compounds. J Org Chem 67:3687–3692

    Article  CAS  PubMed  Google Scholar 

  12. Karimi F, Kihlberg T et al (2001) [11C/13C]Carbon monoxide in palladium-mediated reactions to prepare 11C-labelled imides. J Chem Soc Perkin Transact I 2001:1528–1531

    Article  Google Scholar 

  13. Karimi F, Långström B (2002) Palladium mediated synthesis of [carboxy-11C]amides and hydrazides using [11C] carbon monoxide. J Chem Soc Perkin I 2002:2111–2115

    Article  Google Scholar 

  14. Karimi F, Långström B (2002) Palladium-mediated carboxylation of aryl halides (triflates) or benzyl halides using (13C)/[11C] carbon monoxide with tetrabutylammonium hydroxide or trimethylphenylammonium hydroxide. J Chem Soc Perkin Trans 1:2256–2259

    Google Scholar 

  15. Karimi F, Långström B (2003) Synthesis of 11C-labelled amides by palladium-mediated carboxamination using [11C] carbon monoxide, in situ activated amines and 1,2,2,6,6-pentamethylpiperidine. Eur J Org Chem 11:2132–2137

    Google Scholar 

  16. Karimi F, Långström B (2003) Synthesis of 11C-amides using [11C] carbon monoxide and in situ activated amines by palladium-mediated carboxaminations. Org Biomol Chem 541–546

  17. Bjurling P, R Reineck et al (1996) Synthia, a compact radiochemistry system for automated production of radiopharmaceuticals. Sixth workshop on targetry and target chemistry, Vancouver, Canada

  18. Forngren BH, Tyrefors N, Markides KE, Langstrom B (2000) Determination of raclopride in human plasma by on-column focusing packed capillary liquid chromatography-electrospray ionisation mass spectrometry. J Chromatogr B Biomed Sci Appl 748:189–195

    Article  CAS  PubMed  Google Scholar 

  19. Bergstrom M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerstrom G, Langstrom B (2000) PET imaging of adrenal cortical tumors with the 11β-hydroxylase tracer11C-metomidate. J Nucl Med 41:275–282

    Google Scholar 

  20. Hartvig P, Bergstrom K, Lindberg B, Lundberg PO, Lundqvist H, Langstrom B, Svard H, Rane A (1984) Kinetics of11C-labeled opiates in the brain of rhesus monkeys. J Pharmacol Exp Ther 230:250–255

    Google Scholar 

  21. Lundberg T, Lindstrom LH, Hartvig P, Eckernas SA, Ekblom B, Lundqvist H, Fasth KJ, Gullberg P, Langstrom B (1989) Striatal and frontal cortex binding of11C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers. Psychopharmacology 99:8–12

    CAS  PubMed  Google Scholar 

  22. Neu H, Hartvig P, Torstenson R, Fasth KJ, Sonesson C, Waters N, Carlsson A, Tedroff J, Langstrom B (1997) Synthesis of [11C-methyl]-(−)-OSU6162, its regional brain distribution and some pharmacological effects of (−)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography. Nucl Med Biol 24:507–511

    Article  CAS  PubMed  Google Scholar 

  23. Feldman HS, Hartvig P, Wiklund L, Doucette AM, Antoni G, Gee A, Ulin J, Langstrom B (1997) Regional distribution of11C-labeled lidocaine, bupivacaine, and ropivacaine in the heart, lungs, and skeletal muscle of pigs studied with positron emission tomography. Biopharm Drug Dispos 18:151–164

    Article  CAS  PubMed  Google Scholar 

  24. Bergstrom M, Cass LM, Valind S, Westerberg G, Lundberg EL, Gray S, Bye A, Langstrom B (1999) Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomography. Clin Pharmacokinet 36[Suppl 1]:33–39

    Google Scholar 

  25. Bergstrom M, Fasth KJ, Kilpatrick G, Ward P, Cable KM, Wipperman MD, Sutherland DR, Langstrom B (2000) Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171--PET studies in rhesus monkey. Neuropharmacology 39:664–670

    Article  CAS  PubMed  Google Scholar 

  26. Hartvig P, Bergström M, Antoni G, Långström B (2002) Positron emission tomography and brain monoamine neurotransmission—entries for study of drug interactions. Curr Pharm Des 8:1417–1434

    CAS  PubMed  Google Scholar 

  27. Lappin G, Garner RC (2003) Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2:233–240

    Article  CAS  PubMed  Google Scholar 

  28. Propper DJ, de Bono J, Saleem A, Ellard S, Flanagan E, Paul J, Ganesan TS, Talbot DC, Aboagye EO, Price P, Harris AL, Twelves C (2003) Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J Clin Oncol 21:203–210

    Article  CAS  PubMed  Google Scholar 

  29. Tilsley DW, Harte RJ, Jones T, Brady F, Luthra SK, Brown G, Price PM (1993) New techniques in the pharmacokinetic analysis of cancer drugs. IV. Positron emission tomography. Cancer Surv 17:425–442

    CAS  PubMed  Google Scholar 

  30. Aboagye EO, Luthra SK, Brady F, Poole K, Anderson H, Jones T, Boobis A, Burtles SS, Price P (2002) Cancer research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. Br J Cancer 86:1052–1056

    Article  CAS  PubMed  Google Scholar 

  31. Holford NH (1990) Concepts and usefulness of pharmacokinetic-pharmacodynamic modelling. Fundam Clin Pharmacol 4[Suppl 2]:93s–101s

    Google Scholar 

  32. Sheiner LB, Steimer JL (2000) Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67–95

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This concept was activated in part in collaboration with GSK promoted by Garth Rapeport and in discussions with the Swedish Medical Product Agency, which is gratefully acknowledged.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mats Bergström.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bergström, M., Grahnén, A. & Långström, B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 59, 357–366 (2003). https://doi.org/10.1007/s00228-003-0643-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-003-0643-x

Keywords

Navigation